BusinessVital Therapies Announces Fourth Quarter and Full Year 2016 Financial ResultsBy Nasdaq OMXMar 7, 2017, 9:01 PM UTC
BusinessBioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with AchondroplasiaBy Nasdaq OMXDec 12, 2016, 1:29 PM UTC
